Sitagliptin add-on to low dosage sulphonylureas: efficacy and safety of combination therapy on glycaemic control and insulin secretion capacity in type 2 diabetes

Abstract

The combination therapy with sitagliptin and low dosage sulphonylureas was safe and effective for glycaemic control. Glucagon loading test indicated that 1 year administration of sitagliptin and sulphonylureas preserved insulin secretion capacity.

Low-dose glimepiride with sitagliptin improves glycemic control without dose-dependency in patients with type 2 diabetes inadequately controlled on high-dose glimepiride

“…Insulin secretion capacity did not predict the efficacy of combination therapy in this study. This result is consistent with a previous study [7].…”

“…This recommendation should be evaluated in terms of its impact on the frequency of severe hypoglycemic episodes and any dosedependency associated with low-dose glimepiride. Recently, Harashima et al reported that combination therapy with sitagliptin and low-dose (≤2 mg/day) glimepiride was safe and effective for glycemic control in Japanese patients with type 2 diabetes [7]. The present study is the first to investigate the dose-dependency of glimepiride, below 2 mg (0.5 mg, 1 mg, and 2 mg), in combination with sitagliptin.…”

Incretin-based therapy: renal effects

“…Небольшие по объему пилотные иссле-дования показали возможность снижения альбуминурии у больных СД2 на фоне терапии ситаглиптином [82][83][84]. Прослежена взаимосвязь выраженности антиальбуми-нурического эффекта препарата с исходной величиной альбуминурии: наиболее заметное снижение ЭАМ про-слеживалось у больных с макроальбуминурией [82,85].…”

The Effects of Glucose-Lowering Therapies on Diabetic Kidney Disease

“…Patients with greater degree of albuminuria at baseline had more decline in mean UACR with sitagliptin [29]. In a 52-week single-arm study, sitagliptin added to sulphonylureas reduced HbA1c by 9 mmol/mol (0.8%), decreased UACR from 76.2 ± 95.6 to 33.0 ± 48.1 mg/g, and elicited a decrease in blood pressure [30]. An ongoing phase 4 RCT is designed to explore effect of sitagliptin given in addition to ACE inhibitor or ARB in reducing microalbuminuria in patients with T2DM (NCT02048904).…”